April 3-4 2023 at Gdansk, Poland and online

What is S-DISCO Days?

The International Master of Science in Sustainable Drug Discovery (S-DISCO) is happy to announce the first ever Sustainable Drug Discovery Days. 

S-DISCO days is an international scientific conference, the aim of which is to raise awareness and expand the knowledge on sustainability in drug discovery. The growing concerns of climate change and the increased risk of pharmaceuticals polluting the environment, as well as the equitable availability of quality medicines, means that immediate action is needed. However, actions should not be catered to benefit only human beings. To tackle this problem, all stakeholders, including humans, animals and the environment should be considered. In short, the goal is to provide the needs of the present without compromising the needs of the future for humans, animals and the environment alike.

Join us on April 3-4 in Gdansk and connect with students, scientists and experts from various institutions and industries. 

Listen to high-profile plenary keynote speeches.

Special exhibitions of proposed future research topics by partner companies and organizations.

Enjoy the activities of the event in-person or online.


Preliminary program (download): 


Important: if you want to present at the S-DISCO Days, you will have to add the abstract during registration. The abstract template can be downloaded here.




Polpharma is the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. They actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia. Being the largest Polish pharmaceutical company, they want to help people to live a healthy life in a healthy world. Social responsibility is an integral part of the management strategy in the company.

In the DruQuaR laboratory, the full life cycle of a drug is being considered from a translational view, i.e. taking into account the regulatory possibilities and constraints. It encompasses early discovery and pre-clinical phases of bioactive peptides and repurposing medicines, as well as pre- and post-approval pharmaceutical quality and sustainability aspects.

In the laboratory of Medicinal Chemistry, problems at the chemistry-life sciences interface are addressed. A large part of their work concentrates on the development of small molecule modulators of new targets. Several of the running projects deal with the design of new lead structures and PROTACs for the treatment of diseases with unmet medical needs.


The Journal of Pharmaceutical Analysis (JPA) is a peer-reviewed open access journal for original research articles, review articles and short communications related to all aspects of pharmaceutical analysis.


Scroll to Top